高缺血风险稳定期心肌梗死患者双联抗血小板降阶治疗:TALOS-AMI随机试验事后分析
该研究为TALOS-AMI随机试验的事后分析,纳入2697例经PCI后1个月内无事件的AMI患者,其中1371例具有高缺血风险特征。
核心结论
- 在稳定期AMI患者中,无论是否存在高缺血风险,无指导的氯吡格雷降阶策略与替格瑞洛为基础DAPT相比,缺血和出血结局一致且无显著交互作用。
研究设计与样本
- TALOS-AMI随机临床试验的事后分析,该试验为开放标签、评估者盲法、多中心设计。
- 纳入2697例AMI患者,PCI后1个月替格瑞洛为基础DAPT期间无事件,随机分为降阶组或替格瑞洛DAPT组。
- 高缺血风险定义为糖尿病或慢性肾脏病病史、多支PCI、至少3处病变、总支架长度>60 mm、至少3枚支架、左主干PCI或分叉PCI至少2枚支架。
主要发现
- 高缺血风险组1371例(50.8%),无高缺血风险组1326例(49.2%)。
关键数值与推荐
- 缺血结局定义为心血管死亡、心肌梗死、缺血性卒中、缺血驱动血运重建或支架血栓的复合终点。
- 出血结局定义为BARC 2、3或5型出血。
临床怎么用
- 对于PCI后1个月无事件的稳定期AMI患者,即使存在高缺血风险特征,从替格瑞洛降阶为氯吡格雷未显著增加缺血风险。
- 高缺血风险患者降阶治疗出血风险数值上较低但未达统计学差异,需个体化评估。
局限性
- 为事后分析,高缺血风险亚组分析未按随机化分层,可能存在残余混杂。
- 高缺血风险组中出血结局比较未达统计学显著性,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with acute myocardial infarction (AMI) who have high ischemic risk, data on the efficacy and safety of the de-escalation strategy of switching from ticagrelor to clopidogrel are lacking. OBJECTIVE: To evaluate the outcomes of the de-escalation strategy compared with dual antiplatelet therapy (DAPT) with ticagrelor in stabilized patients with AMI and high ischemic risk following percutaneous coronary intervention (PCI). DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) trial, an open-label, assessor-blinded, multicenter, randomized clinical trial. Patients with AMI who had no event during 1 month of ticagrelor-based DAPT after PCI were included. High ischemic risk was defined as having a history of diabetes or chronic kidney disease, multivessel PCI, at least 3 lesions treated, total stent length greater than 60 mm, at least 3 stents implanted, left main PCI, or bifurcation PCI with at least 2 stents. Data were collected from February 14, 2014, to January 21, 2021, and analyzed from December 1, 2021, to June 30, 2022. INTERVENTION: Patients were randomly assigned to either de-escalation from ticagrelor to clopidogrel or ticagrelor-based DAPT. MAIN OUTCOMES AND MEASURES: Ischemic outcomes (composite of cardiovascular death, myocardial infarction, ischemic stroke, ischemia-driven revascularization, or stent thrombosis) and bleeding outcomes (Bleeding Academic Research Consortium type 2, 3, or 5 bleeding) were evaluated. RESULTS: Of 2697 patients with AMI (mean [SD] age, 60.0 [11.4] years; 454 [16.8%] female), 1371 (50.8%; 684 assigned to de-escalation and 687 assigned to ticagrelor-based DAPT) had high ischemic risk features and a significantly higher risk of ischemic outcomes than those without high ischemic risk (1326 patients [49.2%], including 665 assigned to de-escalation and 661 assigned to ticagrelor-based DAPT) (hazard ratio [HR], 1.74; 95% CI, 1.15-2.63; P = .01). De-escalation to clopidogrel, compared with ticagrelor-based DAPT, showed no significant difference in ischemic risk across the high ischemic risk group (HR, 0.88; 95% CI, 0.54-1.45; P = .62) and the non-high ischemic risk group (HR, 0.65; 95% CI, 0.33-1.28; P = .21), without heterogeneity (P for interaction = .47). The bleeding risk of the de-escalation group was consistent in both the high ischemic risk group (HR, 0.64; 95% CI, 0.37-1.11; P = .11) and the non-high ischemic risk group (HR, 0.42; 95% CI, 0.24-0.75; P = .003), without heterogeneity (P for interaction = .32). CONCLUSIONS AND RELEVANCE: In stabilized patients with AMI, the ischemic and bleeding outcomes of an unguided de-escalation strategy with clopidogrel compared with a ticagrelor-based DAPT strategy were consistent without significant interaction, regardless of the presence of high ischemic risk.
引用
- Lee, Byun, Lim, et al. Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 38117483. doi:10.1001/jamacardio.2023.4587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。